Estee Lauder (EL) announced a collaboration with biotechnology company, Serpin Pharma, that aims to explore how their anti-inflammatory research can be applied in cosmetics to deliver significant skin care longevity benefits to consumers around the world. Serpin Pharma identified a key portion of a superfamily of proteins called SERPINs that enhance the body’s natural ability to heal cells experiencing inflammation. Together, the companies are investigating how this innovative technology, which leverages the body’s innate immune response, can be harnessed to address skin irritation, aging, and sensitivity.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EL:
- Cautious Outlook on Estée Lauder Amid Uncertainty and Strategic Risks
- How Valentine’s Day Ignites a Multi-Billion-Dollar Love Affair with Profit
- Estee Lauder call volume above normal and directionally bullish
- Estee Lauder price target lowered to $64 from $71 at Barclays
- Estee Lauder price target lowered to $85 from $90 at BofA